ALT
What one share of Altimmune holds
Pharmaceutical Preparations
We obtained pemvidutide as part of the acquisition Spitfire Pharma Inc., in July of 2019. Pemvidutide was designed as a MASH therapeutic based on the understanding that targeting both metabolic and liver-specific effects could lead to an improved and differentiated candidate.
Altimmune’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.73 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.61 |
| Cash and investments | $0.32 |
| Debt | $0.18 |
| Book value | $2.44 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $1.48 | $88.57 | $0.06 | −$2.96 | — | — |
| 2017 | $24.86 | −$118.91 | $0.26 | −$47.07 | — | $64.74 |
| 2018 | $3.69 | −$15.16 | $0.35 | −$3.70 | — | — |
| 2019 | $0.44 | −$1.60 | $0.00 | −$0.73 | — | $2.97 |
| 2020 | $0.32 | −$1.91 | $0.01 | −$1.35 | — | $6.08 |
| 2021 | $0.11 | −$2.35 | $0.29 | −$2.19 | — | $4.86 |
| 2022 | −$0.00 | −$1.81 | $0.00 | −$1.34 | — | $3.77 |
| 2023 | $0.01 | −$1.66 | $0.00 | −$1.42 | — | $2.75 |
| 2024 | $0.00 | −$1.34 | — | −$1.12 | — | $1.71 |
| 2025 | $0.00 | −$1.00 | $0.00 | −$0.77 | — | $2.03 |